← All trials
NCT07288749
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2026
- Primary completion
- Dec 31, 2030
- Completion date
- Dec 31, 2031
- First posted
- Dec 17, 2025
- Last posted
- Dec 17, 2025
- Enrollment
- 1484
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Huazhong University of Science and TechnologyLead sponsor
- Anhui Medical UniversityCollaborator
- Capital Medical UniversityCollaborator
- Chinese Academy of Medical SciencesCollaborator
- Xinjiang Medical UniversityCollaborator
- China Medical UniversityCollaborator
- Sichuan Huaxi HopsitalCollaborator
- Nanjing Medical UniversityCollaborator
- Central South UniversityCollaborator
- Fudan UniversityCollaborator
- Southwest Medical UniversityCollaborator
- People's Liberation Army of ChinaCollaborator
- Zhengzhou UniversityCollaborator
- Tianjin Medical UniversityCollaborator
- Huazhong University of Science and TechnologySponsor investigator
- Wuhan Central HospitalCollaborator
- Central South UniversityCollaborator
- Xiamen UniversityCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.